The Evidence Base
@theevidencebase.bsky.social
Providing the latest news, opinion and insight into hot topics including real-world data, health economics and outcomes research and patient-centric care.
Why misaligned evidence strategies delay #PatientAccess to medicines | Becaris Publishing becarispublishing.com/digital-cont...
Why misaligned evidence strategies delay patient access to medicines | Becaris Publishing
becarispublishing.com
February 10, 2026 at 1:09 PM
Why misaligned evidence strategies delay #PatientAccess to medicines | Becaris Publishing becarispublishing.com/digital-cont...
BC Platforms and OmicsBank launch collaboration to grow real-world and multi-omics evidence from India and the UAE | Becaris Publishing becarispublishing.com/digital-cont...
BC Platforms and OmicsBank launch collaboration to grow real-world and multi-omics evidence from India and the UAE | Becaris Publishing
becarispublishing.com
February 9, 2026 at 5:01 PM
BC Platforms and OmicsBank launch collaboration to grow real-world and multi-omics evidence from India and the UAE | Becaris Publishing becarispublishing.com/digital-cont...
TrumpRx launches to lower US drug prices, but early reaction is mixed | Becaris Publishing becarispublishing.com/digital-cont... #DrugPricing #MFN #MostFavoredNation #MarketAccess
TrumpRx launches to lower US drug prices, but early reaction is mixed | Becaris Publishing
becarispublishing.com
February 6, 2026 at 4:21 PM
TrumpRx launches to lower US drug prices, but early reaction is mixed | Becaris Publishing becarispublishing.com/digital-cont... #DrugPricing #MFN #MostFavoredNation #MarketAccess
#RareDisease outcome assessment under #EUHTA and #JointClinicalAssessment | Becaris Publishing becarispublishing.com/digital-cont...
Rare disease outcome assessment under EU HTA and joint clinical assessment | Becaris Publishing
becarispublishing.com
February 5, 2026 at 1:58 PM
#RareDisease outcome assessment under #EUHTA and #JointClinicalAssessment | Becaris Publishing becarispublishing.com/digital-cont...
Hot off the press: Part one of our pick of articles within #HTA and #RWE published in January 2026 | Becaris Publishing becarispublishing.com/digital-cont...
Hot off the press: Part one of our pick of articles within HTA and RWE published in January 2026 | Becaris Publishing
becarispublishing.com
February 5, 2026 at 11:39 AM
Hot off the press: Part one of our pick of articles within #HTA and #RWE published in January 2026 | Becaris Publishing becarispublishing.com/digital-cont...
Reposted by The Evidence Base
📢New article alert
New Perspective article on "Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial"
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #TrialMethodology #RealWorldEvidence #RWE
New Perspective article on "Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial"
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #TrialMethodology #RealWorldEvidence #RWE
Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial
External comparator (EC) studies can improve identification of compounds with the
most promising performance in pre-pivotal single-arm trials (SAT). As SAT output lacks
comparative insights, EC studie...
becarispublishing.com
February 4, 2026 at 5:58 PM
📢New article alert
New Perspective article on "Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial"
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #TrialMethodology #RealWorldEvidence #RWE
New Perspective article on "Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial"
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #TrialMethodology #RealWorldEvidence #RWE
Head-to-head real-world study reports overall survival advantage with apalutamide compared with darolutamide in metastatic castration-sensitive #ProstateCancer | Becaris Publishing becarispublishing.com/digital-cont...
Head-to-head real-world study reports overall survival advantage with apalutamide compared with darolutamide in metastatic castration-sensitive prostate cancer | Becaris Publishing
becarispublishing.com
February 4, 2026 at 10:48 AM
Head-to-head real-world study reports overall survival advantage with apalutamide compared with darolutamide in metastatic castration-sensitive #ProstateCancer | Becaris Publishing becarispublishing.com/digital-cont...
#IndustryUpdate tracker: January 2026 | Becaris Publishing becarispublishing.com/digital-cont...
Industry update tracker: January 2026 | Becaris Publishing
becarispublishing.com
February 2, 2026 at 1:28 PM
#IndustryUpdate tracker: January 2026 | Becaris Publishing becarispublishing.com/digital-cont...
Patient roles and expectations in effective #HTA engagement | Becaris Publishing becarispublishing.com/digital-cont...
Patient roles and expectations in effective HTA engagement | Becaris Publishing
becarispublishing.com
February 2, 2026 at 12:50 PM
Patient roles and expectations in effective #HTA engagement | Becaris Publishing becarispublishing.com/digital-cont...
Reposted by The Evidence Base
📢New article alert
New Research Article on “Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #ColorectalCancer #Oncology #ITC
New Research Article on “Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #ColorectalCancer #Oncology #ITC
Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer
Aim: In the single-arm MOUNTAINEER trial (NCT03043313) tucatinib in combination with trastuzumab showed an objective response rate (ORR)
of 39.3% in patients with previously treated, HER2+ unresectabl...
becarispublishing.com
January 30, 2026 at 11:01 AM
📢New article alert
New Research Article on “Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #ColorectalCancer #Oncology #ITC
New Research Article on “Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #ColorectalCancer #Oncology #ITC
#CMS announces drugs selected for third cycle of #Medicare #DrugPrice negotiations | Becaris Publishing becarispublishing.com/digital-cont...
CMS announces drugs selected for third cycle of Medicare drug price negotiations | Becaris Publishing
becarispublishing.com
January 29, 2026 at 4:37 PM
#CMS announces drugs selected for third cycle of #Medicare #DrugPrice negotiations | Becaris Publishing becarispublishing.com/digital-cont...
Reposted by The Evidence Base
📢New Research Article alert
"Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective"
🔗 becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #KidneyDisease
"Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective"
🔗 becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #KidneyDisease
Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective
Aim: Proteinuria poses a significant challenge in focal segmental glomerulosclerosis (FSGS),
particularly when resistant to standard treatments. Acthar® Gel, a Food and Drug Administration (FDA)-appro...
becarispublishing.com
January 29, 2026 at 4:32 PM
📢New Research Article alert
"Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective"
🔗 becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #KidneyDisease
"Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective"
🔗 becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #KidneyDisease
Modeling #caregiver quality of life in #HTA: Why economic models struggle to reflect lived experience | Becaris Publishing becarispublishing.com/digital-cont...
Modeling caregiver quality of life in HTA: Why economic models struggle to reflect lived experience | Becaris Publishing
becarispublishing.com
January 29, 2026 at 1:05 PM
Modeling #caregiver quality of life in #HTA: Why economic models struggle to reflect lived experience | Becaris Publishing becarispublishing.com/digital-cont...
Reposted by The Evidence Base
📢New article alert
New Short Report on "First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis".
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess
New Short Report on "First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis".
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis
Aim: To compare characteristics of patients with anticitrullinated protein antibody-positive
(ACPA+) and rheumatoid factor-positive (RF+) rheumatoid arthritis (RA) who initiated
abatacept or a tumor n...
becarispublishing.com
January 29, 2026 at 12:25 PM
📢New article alert
New Short Report on "First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis".
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess
New Short Report on "First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis".
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess
New in the Journal of Comparative Effectiveness Research: Video Snapshots | Becaris Publishing becarispublishing.com/digital-cont...
New in the Journal of Comparative Effectiveness Research: Video Snapshots | Becaris Publishing
becarispublishing.com
January 28, 2026 at 12:10 PM
New in the Journal of Comparative Effectiveness Research: Video Snapshots | Becaris Publishing becarispublishing.com/digital-cont...
FDA draft guidance clarifies use of Bayesian methods in #ClinicalTrials | Becaris Publishing becarispublishing.com/digital-cont...
FDA draft guidance clarifies use of Bayesian methods in clinical trials | Becaris Publishing
becarispublishing.com
January 27, 2026 at 3:32 PM
FDA draft guidance clarifies use of Bayesian methods in #ClinicalTrials | Becaris Publishing becarispublishing.com/digital-cont...
Reposted by The Evidence Base
📢New article alert
New Review article on “Reshaping the cardiovascular continuum in the management of arterial and venous cardiovascular disease: a narrative review”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #CardiovascularDisease #Prevention #IntegratedCare
New Review article on “Reshaping the cardiovascular continuum in the management of arterial and venous cardiovascular disease: a narrative review”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #CardiovascularDisease #Prevention #IntegratedCare
Reshaping the cardiovascular continuum in the management of arterial and venous cardiovascular disease: a narrative review
The prevalence of cardiovascular disease (CVaD) is expected to double in the next
25 years, fueled by increasing prevalence of diabetes mellitus, obesity and hypertension.
Cardiovascular–kidney–m...
becarispublishing.com
January 26, 2026 at 2:27 PM
📢New article alert
New Review article on “Reshaping the cardiovascular continuum in the management of arterial and venous cardiovascular disease: a narrative review”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #CardiovascularDisease #Prevention #IntegratedCare
New Review article on “Reshaping the cardiovascular continuum in the management of arterial and venous cardiovascular disease: a narrative review”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #CardiovascularDisease #Prevention #IntegratedCare
Health Canada opens consultation on draft guidance for decentralized clinical trials | Becaris Publishing becarispublishing.com/digital-cont...
Health Canada opens consultation on draft guidance for decentralized clinical trials | Becaris Publishing
becarispublishing.com
January 26, 2026 at 12:41 PM
Health Canada opens consultation on draft guidance for decentralized clinical trials | Becaris Publishing becarispublishing.com/digital-cont...
Reposted by The Evidence Base
📢New article alert
New Research Article on “The impact of socioeconomic crisis on cancer patient outcomes in Lebanon, 2018–2020”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #Oncology #GlobalHealth #HealthEquity #HealthPolicy
New Research Article on “The impact of socioeconomic crisis on cancer patient outcomes in Lebanon, 2018–2020”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #Oncology #GlobalHealth #HealthEquity #HealthPolicy
The impact of socioeconomic crisis on cancer patient outcomes in Lebanon, 2018–2020
Aim: The goal of this study was to assess the impact of economic and social crisis on
access to cancer care in Lebanon. Materials & methods: A cancer Drug Access Program in Lebanon was launched, c...
becarispublishing.com
January 26, 2026 at 10:11 AM
📢New article alert
New Research Article on “The impact of socioeconomic crisis on cancer patient outcomes in Lebanon, 2018–2020”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #Oncology #GlobalHealth #HealthEquity #HealthPolicy
New Research Article on “The impact of socioeconomic crisis on cancer patient outcomes in Lebanon, 2018–2020”.
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #Oncology #GlobalHealth #HealthEquity #HealthPolicy
Reposted by The Evidence Base
📢New article alert
New Short Report on "Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide".
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #ProstateCancer #RWE
New Short Report on "Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide".
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #ProstateCancer #RWE
Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide
Aim: There is limited real-world evidence about prostate-specific antigen (PSA) response
to androgen receptor pathway inhibitor treatment in Black patients with metastatic
castration-sensitive prostat...
becarispublishing.com
January 23, 2026 at 4:47 PM
📢New article alert
New Short Report on "Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide".
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #ProstateCancer #RWE
New Short Report on "Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide".
🔗Read here: becarispublishing.com/doi/10.57264...
#OpenAccess #JCER #ProstateCancer #RWE
ISPOR’s 2026–2027 Top HEOR Trends highlight the growing role of #AI, #RealWorldEvidence, and #ValueBasedHealthcare | Becaris Publishing becarispublishing.com/digital-cont...
Becaris Publishing
becarispublishing.com
January 22, 2026 at 9:58 AM
ISPOR’s 2026–2027 Top HEOR Trends highlight the growing role of #AI, #RealWorldEvidence, and #ValueBasedHealthcare | Becaris Publishing becarispublishing.com/digital-cont...
EU HTA Regulation: One year on, what has changed for patient involvement? | Becaris Publishing becarispublishing.com/digital-cont...
Becaris Publishing
becarispublishing.com
January 21, 2026 at 10:01 AM
EU HTA Regulation: One year on, what has changed for patient involvement? | Becaris Publishing becarispublishing.com/digital-cont...
Ro and Amgen to examine barriers to #GLP-1 access in #obesity care using #RealWorldData | Becaris Publishing becarispublishing.com/digital-cont...
Becaris Publishing
becarispublishing.com
January 19, 2026 at 10:20 AM
Ro and Amgen to examine barriers to #GLP-1 access in #obesity care using #RealWorldData | Becaris Publishing becarispublishing.com/digital-cont...
Trump administration announces “Great Healthcare Plan” proposal centered on legislative action to secure #most-favored-nation #DrugPricing | Becaris Publishing becarispublishing.com/digital-cont...
Becaris Publishing
becarispublishing.com
January 16, 2026 at 4:18 PM
Trump administration announces “Great Healthcare Plan” proposal centered on legislative action to secure #most-favored-nation #DrugPricing | Becaris Publishing becarispublishing.com/digital-cont...
EMA and FDA align on principles for use of #AI across the medicines lifecycle | Becaris Publishing becarispublishing.com/digital-cont...
Becaris Publishing
becarispublishing.com
January 16, 2026 at 12:45 PM
EMA and FDA align on principles for use of #AI across the medicines lifecycle | Becaris Publishing becarispublishing.com/digital-cont...